Validation of a Radiosensitivity Molecular Signature in ...clincancerres.aacrjournals.org/content/clincanres/early/2012/07/25/... · Validation of a Radiosensitivity Molecular Signature
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Validation of a Radiosensitivity Molecular Signature in Breast
Cancer
Steven A. Eschrich, Ph.D.,1 , William J. Fulp, M.S.,2 Yudi Pawitan, Ph.D.,5 John
A. Foekens, Ph.D.,6 Marcel Smid, B.S. 6, John W. M. Martens, M.D. 6, Michelle
Echevarria, M.S.,7 Vidya Kamath, Ph.D.,1 Ji-Hyun Lee, Dr.PH.,2 Eleanor E.
Harris, M.D.,4 Jonas Bergh, M.D.8 and Javier F. Torres-Roca, M.D.3,4
Department of 1Bioinformatics, 2Biostatistics, 3Experimental Therapeutics, and
4Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL
Department of 5Medical Epidemiology and Biostatistics, Karolinska Institutet,
Stockholm, Sweden
Department of 6Medical Oncology and Cancer Genomics, Erasmus Medical
Center Rotterdam, Rotterdam, Netherlands
7Ponce School of Medicine, Ponce, PR
Department of 8Oncology, Radiumhemmet, Karolinska Institutet and University
Hospital, Stockholm, Sweden
Running Title : A Radiosensitivity Molecular Signature in Breast Cancer
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
integrate individual tumor biology with clinical decision-making in radiation
oncology.
References 1. Peters LJ. The ESTRO Regaud lecture Inherent radio sensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiotherapy and Oncology1990 March 1990;17(3):177. 2. Peters LJ, Brock WA, Chapman JD, Wilson G. Predictive assays of tumor radiocurability. Am J Clin Oncol1988 June 1988;11(3):275-87. 3. Perez C. Principles and Management of Radiation Therapy. Philadelphia-NewYork: Lippincott-Raven; 1998. 4. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin2011 Mar-Apr;61(2):91-112. 5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002 Dec 19;347(25):1999-2009. 6. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002 Jan 31;415(6871):530-6. 7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004 Dec 30;351(27):2817-26. 8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008 Apr 1;26(10):1626-34. 9. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008 Oct 23;359(17):1757-65. 10. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010 Feb;11(2):121-8. 11. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010 Jun 24;362(25):2380-8. 12. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer Research.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol2011 Oct;12(11):1004-12. 13. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. International journal of cancer2008 Feb 1;122(3):595-602. 14. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol2005 Nov;48(5):745-51. 15. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, III, Wolkov HB, et al. Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy: An Analysis of Patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res2004 June 15, 2004;10(12):4118-24. 16. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 Staining Is a Strong Predictor of Distant Metastasis and Mortality for Men With Prostate Cancer Treated With Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol2004 June 1, 2004;22(11):2133-40. 17. Eschrich S, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys2009 Oct 1;75(2):497-505. 18. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys2009 Oct 1;75(2):489-96. 19. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, et al. Prediction of Radiation Sensitivity Using a Gene Expression Classifier. Cancer Res2005 August 15, 2005;65(16):7169-76. 20. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res2005;7(6):R953-64. 21. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet2005 Feb 19-25;365(9460):671-9. 22. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res2008 May 1;68(9):3108-14. 23. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol2007 Apr;18(4):694-700. 24. Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, Klijn JG, et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer2007;7:182.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics2003 Apr;4(2):249-64. 26. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res2003 Feb 15;31(4):e15. 27. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics2003 Jan 22;19(2):185-93. 28. Dalton WS, Friend SH. Cancer biomarkers--an invitation to the table. Science2006 May 26;312(5777):1165-8. 29. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst2009 Nov 4;101(21):1446-52. 30. Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol Oncol2008 Apr;1(4):406-12. 31. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol2010 Oct;21 Suppl 7:vii36-40. 32. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet2005 Dec 17;366(9503):2087-106. 33. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med1997 Oct 2;337(14):949-55. 34. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet1999 May 15;353(9165):1641-8. 35. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst2005 Jan 19;97(2):116-26. 36. Whelan TJ, Olivotto I, Ackerman I, Chapman JW, Chua B, Nabid A, et al., editors. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. ASCO; 2011: J Clin Oncol. 37. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res2006 Oct 1;12(19):5705-12. 38. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res2009 Jun 15;15(12):4181-90. 39. Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, et al. Search for a gene expression signature of breast cancer local recurrence in young women. Clin Cancer Res2012 Mar 15;18(6):1704-15. Research.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
40. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol2010 Apr 1;28(10):1677-83. 41. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol2010 Apr 1;28(10):1684-91. 42. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol2011 Jul 20;29(21):2852-8.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Table 2. Multivariate Cox Regression Analysis of RT-Treated Patients
ERASMUS (n=273) (Ref vs. Level) Hazard Ratio p value RSI (RS vs. RR) 1.641 (0.950, 2.836) 0.0758 ER/PR (ER+PR+ vs. ER-PR-) 1.246 (0.747, 2.080) 0.3995 (ER+PR+ vs. ER+PR- or ER-PR+) 1.134 ((0.685, 1.879) 0.6249 T-stage (T1 vs. T2,T3,T4) 1.325 (0.853, 2.057) 0.2106 Age (26-40 vs. 41-55) 0.810 (0.445, 1.471) 0.4882 (26-40 vs. 56-70) 0.891 (0.478, 1.659) 0.7152 (26-40 vs. 71-83) 0.312 (0.103, 0.947) 0.0398 Surgery (Mastectomy vs. Lumpectomy) 1.467 (0.716, 3.006) 0.2956
KAROLINSKA (n=75) (Ref vs. Level) Hazard Ratio p value RSI (RS vs. RR) 5.533 (0.726,42.15) 0.0987 ER/PR (ER+PR+ vs. ER-PR-) 0.684 (0.122, 3.836) 0.6662 (ER+PR+ vs. ER+PR- or ER-PR+) 2.321 (0.715, 7.541) 0.1613 T-stage (T1 vs. T2,T3,T4) 1.452 (0.535, 3.937) 0.464 LN (No vs. Yes) 1.395 (0.42, 4.629) 0.5863 ET (No vs. Yes) 0.433 (0.123, 1.525) 0.1926 CT (No vs. Yes) 0.83 (0.199, 3.465) 0.7978
Table 3. Multivariate Cox Regression Analysis of RT-Treated ER+ Patients
ERASMUS (n=176) (Ref vs. Level) Hazard Ratio p value
RSI (RS vs. RR) 2.640 (1.281, 5.438) 0.0085 PR (PR+ vs. PR-) 1.746 (1.020, 2.988) 0.0423 T-stage (T1 vs. T2,T3,T4) 1.525 (0.872, 2.666) 0.1390 Age (26-40 vs. 41-55) 0.491 (0.230, 1.052) 0.0673 (26-40 vs. 56-70) 0.534 (0.241, 1.184) 0.1226 (26-40 vs. 71-83) 0.225 (0.069, 0.732) 0.0132 Surgery (Mastectomy vs. Lumpectomy) 1.865 (0.702, 4.952 0.2112
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891
Published OnlineFirst July 25, 2012.Clin Cancer Res Steven Eschrich, William J Fulp, Yudi Pawitan, et al. CancerValidation of a Radiosensitivity Molecular Signature in Breast
Updated version
10.1158/1078-0432.CCR-12-0891doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2012/07/25/1078-0432.CCR-12-0891To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 25, 2012; DOI: 10.1158/1078-0432.CCR-12-0891